Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population.

Autor: Buckley A; Imperial College London Diabetes Centre (ICLDC), Abu Dhabi, UAE., Suliman S; Imperial College London Diabetes Centre (ICLDC), Abu Dhabi, UAE., Allum M; Imperial College London Diabetes Centre (ICLDC), Abu Dhabi, UAE., Mohammed N; Imperial College London Diabetes Centre (ICLDC), Abu Dhabi, UAE., Lessan N; Imperial College London Diabetes Centre (ICLDC), Abu Dhabi, UAE., le Roux CW; Divisions of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.; Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland., Suliman M; Imperial College London Diabetes Centre (ICLDC), Abu Dhabi, UAE.
Jazyk: angličtina
Zdroj: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Aug; Vol. 26 (8), pp. 3381-3391. Date of Electronic Publication: 2024 May 24.
DOI: 10.1111/dom.15680
Abstrakt: Aim: Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) dual receptor agonist (RA) that reduces glycated haemoglobin (HbA1c) and weight in patients with type 2 diabetes. We assessed the effectiveness of tirzepatide in real-world use in an Arab population.
Methods: Review of clinical data from a specialist outpatient diabetes centre; study time points and outcome measures were pre-specified.
Results: Tirzepatide was initiated in 8945 patients between 24 October 2022 and 31 December 2023. Of these, 3686 individuals reached 40 weeks of follow-up. At initiation, the mean ± SD age was 54.1 ± 11.5 years, body mass index 34.6 ± 6.0 kg/m 2 and HbA1c 7.3 ± 1.5% (56 ± 17 mmol/mol); 2296 (62%) were switched to tirzepatide from another GLP-RA and 317 (8.6%) reported previous bariatric surgery. The maximum dose dispensed was ≥12.5 mg/week in 1087, 7.5-10.0 mg/week in 1688 and 2.5-5.0 mg/week in 911. The mean 40-week reduction in HbA1c was 0.6 ± 1.2% (8 ± 13 mmol/mol) and the reduction in weight was 4.5 ± 6.9 kg (4.8 ± 7.3%). GLP-RA-naïve patients experienced a significantly greater reduction in HbA1c [1.0 ± 1.3% (11 ± 14 mmol/mol) versus 0.5 ± 1.2% (6 ± 13 mmol/mol), p < .0001] and weight (7.2 ± 8.6 vs. 4.2 ± 6.6 kg, p < .0001) compared with previously exposed individuals. Post-metabolic bariatric surgery patients lost significantly more weight (7.8 ± 9.4 vs. 4.5 ± 7.0 kg, p < .0001). Improvements in blood pressure, lipid profile, and liver transaminases were noted at 40 weeks. Tirzepatide was well tolerated, with 288 (7.8%) of patients discontinuing treatment because of adverse effects, predominantly gastrointestinal.
Conclusion: In real-world use, tirzepatide significantly reduced HbA1c levels and weight and was well tolerated. Previous GLP-RA use was associated with significantly lesser HbA1c and weight reduction, and previous metabolic bariatric surgery was associated with greater weight loss.
(© 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: